Quote:

---

I am not sure that Leronlimab itself is on complete lockdown hold by the FDA.

---

It's not. But when it comes to safety the FDA is much less likely to approve a protocol until the safety concerns are cleared up.

Quote:

---

Still wondering what happened to all of the oncology talk from months ago as that was to be CYDY's main focus, but as we know, was never mentioned in the latest CC.

---

With limited funds Cytodyn is going to look at the cost of a trial, the length of the trial, which indication has a greater likelihood of approval and the potential profit once approved. With NASH costs would be similar, length would be shorter. With no approvals and no competitor to measure against there's a higher likelihood of approval. When it comes to profit, no competitors and a large patient population gives NASH the win.